

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6484545

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	RUTH WATKINSON	01/07/2021
RECEIVING PARTY DATA		
Name:	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	
Street Address:	ONE GUSTAVE L. LEVY PLACE	
City:	NEW YORK	
State/Country:	NEW YORK	
Postal Code:	10029	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	16311887
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	609-896-3600	
Email:	ipdocket@foxrothschild.com	
Correspondent Name:	FOX ROTHSCHILD LLP / MOUNT SINAI	
Address Line 1:	997 LENOX DRIVE, BUILDING 3	
Address Line 4:	LAWRENCEVILLE, NEW JERSEY 08648-2311	
ATTORNEY DOCKET NUMBER:	084284.00168	
NAME OF SUBMITTER:	MIYUKI SHIMIZU	
SIGNATURE:	/Miyuki Shimizu/	
DATE SIGNED:	01/07/2021	
Total Attachments: 3		
source=Assignment-Watkinson#page1.tif		
source=Assignment-Watkinson#page2.tif		
source=Assignment-Watkinson#page3.tif		

PATENT ASSIGNMENT

Ruth Watkinson, c/o Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place New York, NY 10029 (referred to as “Assignor(s)”) has made an invention(s) (the “Invention(s)”) set forth in an application for patent of the United States entitled:

VIRAL DELIVERY OF RNA UTILIZING SELF-CLEAVING RIBOZYMES AND CRISPR-BASED APPLICATIONS THEREOF

and which is a

(1) ☐ Provisional Application

- (a) ☐ to be filed herewith; or
(b) ☐ bearing Application No. _____,
and filed on _____; or

(2) ☒ Non-Provisional Application

- (a) ☐ to be filed herewith; or
(b) ☒ bearing Application No. 16/311,887, and filed on
December 20, 2018.

WHEREAS ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, an academic institution organized under the laws of New York, having a place of business at One Gustave L. Levy Place, New York, NY 10029, United States; and its successors and assigns (collectively hereinafter called “the Assignee”), is desirous of acquiring the entire right, title, and interest in: the Invention(s); the application for patent identified in paragraph (1) or (2); the right to file applications for patent of the United States or other countries on the Invention(s); any application(s) for patent of the United States or other countries claiming priority to these application(s); any provisional or other right to recover damages, including royalties, for prior infringements of these applications; and any patent(s) of the United States or other countries that may be granted therefor or thereon.

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that the Assignors have not done so already via a prior agreement with the Assignee, or if the Assignors have already done so via a prior agreement with the Assignee then in confirmation of any obligation to do so in said prior agreement, the Assignors have sold, assigned, transferred, and set over, and by these presents do sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns, the Assignors’ entire right, title, and interest in:

- (a) the Invention(s);
- (b) the application for patent identified in paragraph (1) or (2);
- (c) the right to file applications for patent of the United States or other countries on the Invention(s), including all rights under the Paris Convention for the Protection of Industrial Property and under the Patent Cooperation Treaty and all member countries;
- (d) any application(s) for patent of the United States or other countries claiming the Invention(s);
- (e) any application(s) for patent of the United States or other countries claiming priority to the application for patent identified in paragraph (1) or (2) or any application(s) for patent claiming the Invention(s), including any division(s), continuation(s), and continuation(s)-in-part; and
- (f) any provisional or other right to recover damages, including royalties, for prior infringements of any application for patent identified in the preceding paragraphs (b)-(e); and
- (g) any patent(s) of the United States or other countries that may be granted for or on any application for patent identified in the preceding paragraphs (b) - (e), including any reissue(s) and extension(s) of said patent(s).

The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, as fully and entirely as the same would have been held and enjoyed by the Assignors had this sale and assignment not been made.

The Assignors hereby covenant and agree to and with the Assignee, its successors, legal representatives, and assigns, that the Assignors will sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done in connection with any and all proceedings for the procurement, maintenance, enforcement and defense of the Invention(s), said applications, and said patents, including interference proceedings, without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

The Assignors hereby authorize and request the attorneys of


Customer No. J25087

to insert in the spaces provided above the filing date, the application number, and the attorney docket number of the application identified in paragraph (1) or (2) when known.

The Assignors hereby request the Commissioner of Patents to issue said patents of the United States to the Assignee for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

I hereby declare subject to the penalty of perjury that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true.

Date: 1/7/2021


Ruth Wilkinson